Amgen Announces New Data Being Presented At ASH 2021
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Source: apnews.com
Page 21 - Randomized Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Randomized Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Randomized Phase Today - Breaking & Trending Today
F. Hoffmann-La Roche Ltd: Roche to present new pivotal data at ASH 2021 from broad and comprehensive portfolio, challenging treatment standards for people with blood disorders
Phase III POLARIX trial showed Polivy plus R-CHP was the first treatment in two decades to significantly improve outcomes in newly diagnosed diffuse large B-cell lymphoma (DLBCL) versus the standard of
Source: finanznachrichten.de
Novartis Pharma AG: New data at ASH spotlight Novartis recently approved Scemblix, next-generation CAR-T platform and expanding hematology portfolio
New longer-term efficacy and safety data from pivotal Phase III ASCEMBL study for recently US-approved Scemblix (asciminib) in patients with PH+ CML-CPEarly findings from YTB323 and PHE885 CAR-T cell therapies
Source: finanznachrichten.de
Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): New data at ASH spotlight Novartis recently approved Scemblix®, next-generation CAR-T platform and expanding hematology portfolio
Investegate announcements from NOVARTIS AG CHF0.50(REGD), New data at ASH spotlight Novartis recently approved Scemblix®, next-generation CAR-T platform and expanding hematology portfolio
Source: investegate.co.uk
AbbVie to Highlight New Advances in Blood Cancer Research and Expanding Oncology Pipeline at 63rd ASH Annual Meeting
ABBVie will present results from nearly 30 abstracts across eight types of cancer during the upcoming American Society of Hematology Annual Meeting in Atlanta, Georgia . "We are dedicated to transforming standards of care for people living with blood cancers," said Mohamed Zaki M.D., Ph.D, vice president and global head of oncology development, AbbVie. "The data we are presenting at the ASH Annual Meeting build on ...
Source: investingnews.com